Cita APA

Millan, O., Rovira, J., Guirado, L., Espinosa, C., Budde, K., Sommerer, C., . . . Brunet, M. (2021). Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation.

Citación estilo Chicago

Millan, O., J. Rovira, L. Guirado, C. Espinosa, K. Budde, C. Sommerer, GJ Pineiro, F. Diekmann, y M. Brunet. Advantages of Plasmatic CXCL-10 As a Prognostic and Diagnostic Biomarker for the Risk of Rejection and Subclinical Rejection in Kidney Transplantation. 2021.

Cita MLA

Millan, O., et al. Advantages of Plasmatic CXCL-10 As a Prognostic and Diagnostic Biomarker for the Risk of Rejection and Subclinical Rejection in Kidney Transplantation. 2021.